|Type||Subsidiary of Novartis|
|Key people||Jeff George, CEO|
|Products||alprazolam, amlodipine, atenolol, amoxicillin, azithromycin, citalopram, enalapril, fentanyl, fluoxetine, lisinopril, loratadine, metformin, metoprolol, midazolam, omeprazole, penicillin, ranitidine, simvastatin, terazosin|
|Revenue||US$7.2 billion (2007)
US$8.5 billion (2010)
US$10.7 billion (2011)
Founded in 1886, Sandoz is a subsidiary of Novartis, a multinational pharmaceutical company. The company develops, manufactures and markets generic drugs as well as pharmaceutical and biotechnological active ingredients. As of 2011[update], Sandoz was the world's second largest generic drug company, with revenue of US$10.7 billion. In 2010, the company reported revenue of US$8.5 billion.
Sandoz employs more than 23,000 people in 130 countries. Its global headquarters are in Holzkirchen, Germany, just south of Munich. Its biggest sites are Boucherville, Quebec, Broomfield, Colorado, Cambé, Kalwa, Kundl, Ljubljana, Gebze, Magdeburg, Stryków, Princeton, New Jersey, and Wilson, North Carolina.
History before Novartis 
Before the 1996 merger with Ciba-Geigy to form Novartis, Sandoz Pharmaceuticals (Sandoz AG) was a pharmaceutical company headquartered in Basel, Switzerland (as was Ciba-Geigy), and was best known for developing drugs such as Sandimmune for organ transplantation, the antipsychotic Clozaril, Mellaril Tablets and Serentil Tablets for treating psychiatric disorders, and Cafergot Tablets and Torecan Suppositories for treating migraine headaches.
Sandoz was also known for one of its scientists, Albert Hofmann, who synthesized LSD in 1938 and by 1949 was marketing it as a psychiatric drug under the trade name Delysid. The Sandoz product received mass publicity as early as 1954, in a Time Magazine feature.
History as part of Novartis 
|This section requires expansion. (May 2012)|
As of May 2012[update], Sandoz planned to acquire Fougera, a dermatology-focused maker of generic and brand-name drugs. Should this acquisition go to completion, it would position Sandoz as the largest maker of generic dermatology drugs in the world.
See also 
- Associated Press (May 3, 2012), "Sandoz Acquiring Fougera for $1.5B", Drug Discovery & Development, dddmag.com, retrieved May 16, 2012
- "Medicine: Dream Stuff". Time. June 28, 1954.